Clinical Trials Directory

Trials / Completed

CompletedNCT00228046

Medication Strategies for Treating Aggressive Behavior in Youth With Attention Deficit Hyperactivity Disorder

Double-Blind, Placebo-Controlled Trial of Flexible Dose Divalproex Sodium Adjunctive to Stimulant Treatment for Aggressive Children With Attention-Deficit Hyperactivity Disorder

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
40 (estimated)
Sponsor
Stony Brook University · Academic / Other
Sex
All
Age
6 Years – 14 Years
Healthy volunteers
Not accepted

Summary

This study will assess whether adding a mood stabilizer, divalproex sodium, to stimulant treatment is more effective than stimulant treatment alone in reducing aggressive behavior among children with attention deficit hyperactivity disorder (ADHD).

Detailed description

ADHD is one of the most common childhood mental disorders. It often causes impaired functioning in multiple areas, including home, school, and peer relationships. Additionally, children with ADHD often develop aggressive behavior, which is not usually adequately suppressed by standard stimulant treatments for ADHD. In order to address this problem, many physicians prescribe multiple medications at once. There is no clinical evidence, however, proving that this method is safe and effective. This study will assess whether adding a mood stabilizer, divalproex sodium, to stimulant treatment is more effective than stimulant treatment alone in reducing aggressive behavior among children with ADHD. Participants in this double blind study will first receive open label stimulant treatment for ADHD and a comorbid disruptive behavior disorder. Participants whose aggressive behavior subsides with stimulant treatment alone will not proceed into the next phase of the study. Participants whose ADHD symptoms lessen from the treatment but whose aggressive behavior persists will be randomly assigned to receive either divalproex sodium or placebo in addition to their stimulant treatment for 8 weeks. Study visits will be held weekly for 11 to 16 weeks. At these visits, aggression levels and medication side effects will be assessed. Families will also meet with the researchers to discuss the child's progress, and attend behavioral counseling with a therapist. Participants who did not continue into the second phase of the study will be asked to return to the study site for a follow-up visit 8 weeks following the end of the first phase.

Conditions

Interventions

TypeNameDescription
DRUGDivalproex Sodium
DRUGMethylphenidate
DRUGDextroamphetamine
DRUGMixed Amphetamine Salts
BEHAVIORALFamily Counseling
BEHAVIORALBehavior Management Training with Parents

Timeline

Start date
2004-01-01
Primary completion
2007-07-01
Completion
2007-07-01
First posted
2005-09-28
Last updated
2013-10-31

Locations

2 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT00228046. Inclusion in this directory is not an endorsement.